Published in Breast Cancer Res on March 17, 2015
Long noncoding RNA CCAT2 promotes breast tumor growth by regulating the Wnt signaling pathway. Onco Targets Ther (2015) 1.03
miR-124 downregulation leads to breast cancer progression via LncRNA-MALAT1 regulation and CDK4/E2F1 signal activation. Oncotarget (2016) 0.88
The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients. Int J Mol Sci (2015) 0.85
Luminal long non-coding RNAs regulated by estrogen receptor alpha in a ligand-independent manner show functional roles in breast cancer. Oncotarget (2016) 0.84
Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer. Breast Cancer Res Treat (2015) 0.82
Roles for miRNAs in endocrine resistance in breast cancer. Endocr Relat Cancer (2015) 0.80
Tamoxifen Resistance: Emerging Molecular Targets. Int J Mol Sci (2016) 0.80
Long non-coding RNA GAS5 inhibits tumorigenesis via miR-137 in melanoma. Am J Transl Res (2017) 0.80
miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Cell Death Dis (2016) 0.78
Long non-coding RNA PVT1 promotes osteosarcoma development by acting as a molecular sponge to regulate miR-195. Oncotarget (2016) 0.78
Understanding breast cancer - The long and winding road. BBA Clin (2017) 0.77
Inflamma-miRs in Aging and Breast Cancer: Are They Reliable Players? Front Med (Lausanne) (2015) 0.76
Breast Cancer Anti-Estrogen Resistance 4 (BCAR4) Drives Proliferation of IPH-926 lobular Carcinoma Cells. PLoS One (2015) 0.76
Dioscin strengthens the efficiency of adriamycin in MCF-7 and MCF-7/ADR cells through autophagy induction: More than just down-regulation of MDR1. Sci Rep (2016) 0.76
Profiles of miRNAs matched to biology in aromatase inhibitor resistant breast cancer. Oncotarget (2016) 0.75
Long Non-Coding RNA (lncRNA) Urothelial Carcinoma-Associated 1 (UCA1) Enhances Tamoxifen Resistance in Breast Cancer Cells via Inhibiting mTOR Signaling Pathway. Med Sci Monit (2016) 0.75
Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Res (2016) 0.75
Cotargeting of CYP-19 (aromatase) and emerging, pivotal signalling pathways in metastatic breast cancer. Br J Cancer (2016) 0.75
Dysregulation of long non-coding RNA in breast cancer: an overview of mechanism and clinical implication. Oncotarget (2016) 0.75
MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy. Oncotarget (2016) 0.75
Targeting microRNAs: a new action mechanism of natural compounds. Oncotarget (2016) 0.75
Recent trends in microRNA research into breast cancer with particular focus on the associations between microRNAs and intrinsic subtypes. J Hum Genet (2016) 0.75
Potential Diagnostic and Therapeutic Applications of Oligonucleotide Aptamers in Breast Cancer. Int J Mol Sci (2017) 0.75
MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 23.55
Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst (1998) 22.10
Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell (2004) 16.10
The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet (2010) 15.87
Long noncoding RNA as modular scaffold of histone modification complexes. Science (2010) 15.23
let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell (2007) 13.69
Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem (1994) 10.75
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol (2008) 7.86
Steroid hormone receptors: many actors in search of a plot. Cell (1995) 7.22
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst (2004) 6.55
Functional domains of the human estrogen receptor. Cell (1987) 6.52
MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol (2007) 6.41
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science (1995) 6.37
Mechanisms of estrogen action. Physiol Rev (2001) 5.97
Noncoding RNA gas5 is a growth arrest- and starvation-associated repressor of the glucocorticoid receptor. Sci Signal (2010) 4.77
The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem (2001) 4.67
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst (2003) 4.45
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res (2010) 3.89
Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther (2004) 3.84
GAS5, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene (2008) 3.79
lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature (2013) 3.77
Delivery materials for siRNA therapeutics. Nat Mater (2013) 3.70
Retracted MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem (2008) 3.63
Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev (1994) 3.54
Integration of the extranuclear and nuclear actions of estrogen. Mol Endocrinol (2005) 3.44
Long noncoding RNAs: past, present, and future. Genetics (2013) 3.16
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer. Proc Natl Acad Sci U S A (2008) 3.08
The rise of regulatory RNA. Nat Rev Genet (2014) 3.02
miR-34 - a microRNA replacement therapy is headed to the clinic. Front Genet (2012) 2.89
Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol (2002) 2.87
Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther (2008) 2.85
MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res (2010) 2.83
LncRNADisease: a database for long-non-coding RNA-associated diseases. Nucleic Acids Res (2012) 2.73
Sources of estrogen and their importance. J Steroid Biochem Mol Biol (2003) 2.54
TGF-β upregulates miR-181a expression to promote breast cancer metastasis. J Clin Invest (2012) 2.44
Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen. Mol Endocrinol (1997) 2.42
Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst (2005) 2.10
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway. Cancer Chemother Pharmacol (2013) 2.09
Widespread estrogen-dependent repression of micrornas involved in breast tumor cell growth. Cancer Res (2009) 1.98
The H19 locus acts in vivo as a tumor suppressor. Proc Natl Acad Sci U S A (2008) 1.98
Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann Oncol (2008) 1.92
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole. Cancer Res (2005) 1.84
Regulation of mammalian cell differentiation by long non-coding RNAs. EMBO Rep (2012) 1.82
Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res (1988) 1.80
miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. Nat Cell Biol (2013) 1.79
CD44 attenuates metastatic invasion during breast cancer progression. Cancer Res (2005) 1.72
Expression of miR-21 and its targets (PTEN, PDCD4, TM1) in flat epithelial atypia of the breast in relation to ductal carcinoma in situ and invasive carcinoma. BMC Cancer (2009) 1.70
Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogenesis (2002) 1.69
Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol (2005) 1.67
Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer. Oncogene (2012) 1.62
Tumor development in the Beckwith-Wiedemann syndrome is associated with a variety of constitutional molecular 11p15 alterations including imprinting defects of KCNQ1OT1. Hum Mol Genet (2001) 1.58
Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance. Oncogene (2011) 1.51
Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res (2003) 1.46
Downregulation of miR-342 is associated with tamoxifen resistant breast tumors. Mol Cancer (2010) 1.46
Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci (2012) 1.44
Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis (2010) 1.42
Antisense transcript long noncoding RNA (lncRNA) HOTAIR is transcriptionally induced by estradiol. J Mol Biol (2013) 1.41
De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med (2012) 1.40
An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol Cell Endocrinol (1992) 1.39
Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res (2011) 1.37
Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol (2011) 1.36
Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A (2011) 1.33
In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res (1998) 1.31
miRNAs and estrogen action. Trends Endocrinol Metab (2012) 1.24
MicroRNA-101-mediated Akt activation and estrogen-independent growth. Oncogene (2010) 1.23
An estrogen-independent MCF-7 breast cancer cell line which contains a novel 80-kilodalton estrogen receptor-related protein. Cancer Res (1995) 1.23
MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat (2010) 1.23
miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS One (2013) 1.18
Estrogen receptors and breast cancer. Epidemiol Rev (1986) 1.17
The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells. Breast Cancer Res Treat (2010) 1.17
The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget (2014) 1.14
High miR-26a and low CDC2 levels associate with decreased EZH2 expression and with favorable outcome on tamoxifen in metastatic breast cancer. Breast Cancer Res Treat (2011) 1.12
Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. Mol Cancer Res (2006) 1.11
Cell cycle regulation by long non-coding RNAs. Cell Mol Life Sci (2013) 1.10
Non-coding RNA interact to regulate neuronal development and function. Front Cell Neurosci (2014) 1.09
Aromatase inhibitor treatment of breast cancer cells increases the expression of let-7f, a microRNA targeting CYP19A1. J Pathol (2012) 1.07
Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice. Cancer Res (2006) 1.07
Oncogenic microRNAs: miR-155, miR-19a, miR-181b, and miR-24 enable monitoring of early breast cancer in serum. BMC Cancer (2014) 1.07
Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol (2014) 1.07
Role of microRNAs in breast cancer. Cancer Biol Ther (2013) 1.07
Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol (2001) 1.06
Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment. Eur J Cancer (2013) 1.04
Reduced expression of miR-200 family members contributes to antiestrogen resistance in LY2 human breast cancer cells. PLoS One (2013) 1.04
Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res (2009) 1.03
Steroid hormones modulate H19 gene expression in both mammary gland and uterus. Oncogene (1999) 1.03
Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer. Cancer Res (2013) 1.02
Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. Int J Cancer (2004) 0.98
Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells. J Cell Physiol (2011) 0.98
MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. J Pathol (2014) 0.96
Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab Dispos (2010) 0.94
The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat (2012) 0.93
Differences between estrogen- and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor. Cancer Res (1984) 0.93
LncRNAs: New Players in Apoptosis Control. Int J Cell Biol (2014) 0.93
Ligand-independent coactivation of ERalpha AF-1 by steroid receptor RNA activator (SRA) via MAPK activation. J Steroid Biochem Mol Biol (2003) 0.92
miR-135b coordinates progression of ErbB2-driven mammary carcinomas through suppression of MID1 and MTCH2. Am J Pathol (2013) 0.90
Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time. Proc Natl Acad Sci U S A (2011) 1.33
Protective effects of dietary antioxidants on proton total-body irradiation-mediated hematopoietic cell and animal survival. Radiat Res (2009) 1.31
Structure-function relationships of estrogenic triphenylethylenes related to endoxifen and 4-hydroxytamoxifen. J Med Chem (2010) 1.05
New hypotheses and opportunities in endocrine therapy: amplification of oestrogen-induced apoptosis. Breast (2009) 0.94
By looking back we can see the way forward: enhancing the gains achieved with antihormone therapy. Breast Cancer Res (2008) 0.88
The Paradox of Oestradiol-Induced Breast Cancer Cell Growth and Apoptosis. Curr Signal Transduct Ther (2009) 0.84
Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant. J Steroid Biochem Mol Biol (2006) 0.84
The Conformation of the Estrogen Receptor Directs Estrogen-Induced Apoptosis in Breast Cancer: A Hypothesis. Horm Mol Biol Clin Investig (2011) 0.81